("Nuformix" or "the Company")
Statement re: Share Price Movement
Nuformix (LSE: NFX.L), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, notes the recent share price movement and confirms that the Company is conducting a number of commercial discussions relating to its product pipeline, however, these meetings are still at an early stage and may or may not result in material agreements for the Company. Further update announcements will be made as and when appropriate.
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L. Follow Nuformix on Vox Markets: follow at: www.voxmarkets.co.uk/company/NFX
and the Company's web site at: www.nuformix.com
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Dan Gooding, Chief Executive Officer
+44 (0)1223 423 667
Gable Communications Ltd
John Bick / Justine James
+44 (0)20 7193 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS